N
Ni Jiang
Researcher at Capital Medical University
Publications - 11
Citations - 194
Ni Jiang is an academic researcher from Capital Medical University. The author has contributed to research in topics: Immunotherapy & Cytokine-induced killer cell. The author has an hindex of 7, co-authored 11 publications receiving 153 citations.
Papers
More filters
Journal ArticleDOI
Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.
Ni Jiang,Guoliang Qiao,Xiaoli Wang,Michael A. Morse,William R. Gwin,Lei Zhou,Yuguang Song,Yanjie Zhao,Feng Chen,Xinna Zhou,Lefu Huang,Amy Hobeika,Xin Yi,Xuefeng Xia,Yanfang Guan,Jin Song,Jun Ren,Jun Ren,H. Kim Lyerly +18 more
TL;DR: Treatment of advanced pancreatic cancer with combined DC-CIK infusions and S-1 was safe, resulted in favorable PFS and OS, and modulated the peripheral blood immune repertoire.
Journal ArticleDOI
Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)
Xiaoli Wang,Xiaoli Wang,Jun Ren,Jun Ren,Jun Ren,Jie Zhang,Ying Yan,Ni Jiang,Jing Yu,Lijun Di,Guohong Song,Li Che,Jun Jia,Xinna Zhou,Xinna Zhou,Huabing Yang,Huabing Yang,Herbert Kim Lyerly +17 more
TL;DR: These data suggested that such combination therapy model be effective and safe for younger metastatic TNBC exposure to previous anthracyclines and taxanes based adjuvant chemotherapy.
Journal ArticleDOI
Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients’ preference-based study (PPPS)
Yanjie Zhao,Guoliang Qiao,Xiaoli Wang,Yuguang Song,Xinna Zhou,Ni Jiang,Lei Zhou,Hongyan Huang,Jing Zhao,Michael A. Morse,Amy Hobeika,Jun Ren,Jun Ren,Herbert Kim Lyerly +13 more
TL;DR: DC-CIK combined with chemotherapy administration resulted in numerically superior PFS and OS compared with monotherapy in advanced NSCLC.
Journal ArticleDOI
Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.
Jun Ren,William R. Gwin,Xinna Zhou,Xiaoli Wang,Hongyan Huang,Ni Jiang,Lei Zhou,Pankaj K. Agarwal,Amy Hobeika,Erika J. Crosby,Zachary C. Hartman,Michael A. Morse,Kevin H. Eng,H. Kim Lyerly +13 more
TL;DR: Strategies inducing the local activation of tumor-specific immune responses can be combined with adoptive cellular therapies to expand the adaptive T cell responses systemically and further studies are warranted.
Journal ArticleDOI
Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors.
Guoliang Qiao,Xiaoli Wang,Xinna Zhou,Michael A. Morse,Jiangping Wu,Shuo Wang,Yuguang Song,Ni Jiang,Yanjie Zhao,Lei Zhou,Jing Zhao,Yan Di,Lihong Zhu,Amy Hobeika,Jun Ren,Jun Ren,Herbert Kim Lyerly +16 more
TL;DR: Combining HT with ACT plus either CT or anti-PD-1 antibody was safe, generated clinical responses in previously treated advanced cancers, and promoted TCR repertoire diversity and favorable changes in serum IL-2, IL-4, TNF-α, and IFN-γ levels in clinical responders.